Effects of budegforo combined with doxofylline on inflammatory indexes, monocyte chemotactic protein 1 and serum amyloid A protein levels in patients with moderate and severe chronic obstructive pulmonary disease during acute exacerbation period
扫码查看
点击上方二维码区域，可以放大扫码查看
原文链接
万方数据
目的 探讨布地格福联合多索茶碱对急性加重期中重度慢性阻塞性肺疾病（COPD）患者炎性反应指标及单核细胞趋化蛋白-1（MCP-1）、血清淀粉样蛋白A（SAA）水平的影响。 方法 采用前瞻性研究的方法，选取2020年1月至2021年12月在湖北省公安县人民医院进行治疗的80例急性加重期中重度COPD患者作为研究对象。采用随机数字表法分为布地格福组和联合组，每组40例。布地格福组在常规维持治疗的基础上给予布地格福吸入气雾剂治疗，联合组在布地格福基础上联合多索茶碱治疗，两组患者均连续治疗12周。比较两组临床总有效率、治疗前后肺功能指标、炎性反应指标、MCP-1、SAA水平及不良反应发生情况。 结果 联合组治疗后总有效率高于布地格福组[95.00%（38/40）比75.00%（30/40）]，差异有统计学意义（χ2 = 4.80，P<0.05）。治疗12周后，联合组第1秒用力呼气容积（FEV1）、FEV1与用力肺活量比值、FEV1占预计值百分比、最大自主通气量、一氧化碳弥散量占预计值百分比高于布地格福组[（2.80 ± 0.56）L比（2.41 ± 0.27）L、（66.35 ± 8.20）%比（61.84 ± 9.77）%、（72.73 ± 7.57）%比（65.39 ± 5.41）%、（73.56 ± 7.06）L/min比（68.53 ± 6.25）L/min、（71.03 ± 5.85）%比（66.37 ± 7.08）%]，残气容积与肺总量比值低于布地格福组[（45.32 ± 6.64）%比（51.73 ± 8.45）%]，差异有统计学意义（P<0.05）。治疗12周后，联合组白细胞介素（IL）-17、IL-22、MCP-1、SAA水平低于布地格福组[（21.46 ± 5.86）ng/L比（30.55 ± 8.74）ng/L、（155.62 ± 14.39）ng/L比（170.81 ± 16.70）ng/L、（89.57 ± 7.41）ng/L比（105.25 ± 8.70）ng/L、（45.21 ± 8.86）ng/L比（57.67 ± 7.16）ng/L]，差异有统计学意义（P<0.05）。两组不良反应发生率比较差异无统计学意义（P>0.05）。 结论 布地格福与多索茶碱联合应用能够提高急性加重期中重度COPD患者肺功能，改善临床疗效，并且对降低MCP-1、SAA水平具有积极作用。 Objective To investigate the effects of budegforo combined with doxofylline on inflammatory indexes, monocyte chemotactic protein 1 (MCP-1) and serum amyloid A protein (SAA) levels in patients with moderate and severe chronic obstructive pulmonary disease (COPD) during exacerbation period. Methods The method of prospective study was adopted, 80 patients with moderate and severe COPD during exacerbation period who were treated in Gongan County People′s Hospital from January 2020 to December 2021 were selected as the research objects, and they were divided into the combined group and the budegforo group by random number table method, with 40 cases in each group. The budegforo group was treated with budegforo inhalation and the conventional maintenance therapy, the combined group was treated with doxofylline on the basis treatment of the budegforo group. The patients of the two groups were treated for 12 weeks. The clinical total effective rate and pulmonary function, inflammatory indexes and MCP-1, SAA levels before and after treatment and adverse reactions of the two groups were compared. Results The clinical total effective rate in the combined group was higher than that in the budegforo group: 95.00%(38/40) vs. 75.00%(30/40), there was statistical difference (χ2 = 4.80, P<0.05). After 12 weeks of treatment, the forced expiratory volume in one second (FEV1), FEV1 and forced vital capacity (FVC) ratio (FEV1/FVC), percentage of FEV1 in predicted value (FEV1% pred), maximum voluntary ventilation (MVV), percentage of predicted value of diffusing capacity of the lung for carbon monoxide (DLCO% pred) in the combined group were higher than those in the budegforo group: (2.80 ± 0.56) L vs. (2.41 ± 0.27) L, (66.35 ± 8.20)% vs. (61.84 ± 9.77)%, (72.73 ± 7.57)% vs. (65.39 ± 5.41)%, (73.56 ± 7.06) L/min vs. (68.53 ± 6.25) L/min, (71.03 ± 5.85)% vs. (66.37 ± 7.08)% residual volume (RV) to total lung capacity (TLC) ratio (RV/TLC) level was lower than that in the budegforo group: (45.32 ± 6.64)% vs. (51.73 ± 8.45)%, there were statistical differences (P<0.05). After 12 weeks of treatment, the levels of interleukin(IL)-17, IL-22, MCP-1, SAA in the combined group were lower than those in the budegforo group: (21.46 ± 5.86) ng/L vs. (30.55 ± 8.74) ng/L, (155.62 ± 14.39) ng/L vs. (170.81 ± 16.70) ng/L, (89.57 ± 7.41) ng/L vs. (105.25 ± 8.70) ng/L, (45.21 ± 8.86) ng/L vs. (57.67 ± 7.16) ng/L, there were statistical differences (P<0.05). There was no statistical difference in adverse reactions between the two groups (P>0.05). Conclusions The application of budegforo combined with doxofylline can improve the pulmonary function and clinical efficacy of patients with moderate and severe COPD during exacerbation period, and also play a positive role in reducing MCP-1 and SAA levels.
Objective To investigate the effects of budegforo combined with doxofylline on inflammatory indexes, monocyte chemotactic protein 1 (MCP-1) and serum amyloid A protein (SAA) levels in patients with moderate and severe chronic obstructive pulmonary disease (COPD) during exacerbation period. Methods The method of prospective study was adopted, 80 patients with moderate and severe COPD during exacerbation period who were treated in Gongan County People′s Hospital from January 2020 to December 2021 were selected as the research objects, and they were divided into the combined group and the budegforo group by random number table method, with 40 cases in each group. The budegforo group was treated with budegforo inhalation and the conventional maintenance therapy, the combined group was treated with doxofylline on the basis treatment of the budegforo group. The patients of the two groups were treated for 12 weeks. The clinical total effective rate and pulmonary function, inflammatory indexes and MCP-1, SAA levels before and after treatment and adverse reactions of the two groups were compared. Results The clinical total effective rate in the combined group was higher than that in the budegforo group: 95.00%(38/40) vs. 75.00%(30/40), there was statistical difference (χ2 = 4.80, P<0.05). After 12 weeks of treatment, the forced expiratory volume in one second (FEV1), FEV1 and forced vital capacity (FVC) ratio (FEV1/FVC), percentage of FEV1 in predicted value (FEV1% pred), maximum voluntary ventilation (MVV), percentage of predicted value of diffusing capacity of the lung for carbon monoxide (DLCO% pred) in the combined group were higher than those in the budegforo group: (2.80 ± 0.56) L vs. (2.41 ± 0.27) L, (66.35 ± 8.20)% vs. (61.84 ± 9.77)%, (72.73 ± 7.57)% vs. (65.39 ± 5.41)%, (73.56 ± 7.06) L/min vs. (68.53 ± 6.25) L/min, (71.03 ± 5.85)% vs. (66.37 ± 7.08)% residual volume (RV) to total lung capacity (TLC) ratio (RV/TLC) level was lower than that in the budegforo group: (45.32 ± 6.64)% vs. (51.73 ± 8.45)%, there were statistical differences (P<0.05). After 12 weeks of treatment, the levels of interleukin(IL)-17, IL-22, MCP-1, SAA in the combined group were lower than those in the budegforo group: (21.46 ± 5.86) ng/L vs. (30.55 ± 8.74) ng/L, (155.62 ± 14.39) ng/L vs. (170.81 ± 16.70) ng/L, (89.57 ± 7.41) ng/L vs. (105.25 ± 8.70) ng/L, (45.21 ± 8.86) ng/L vs. (57.67 ± 7.16) ng/L, there were statistical differences (P<0.05). There was no statistical difference in adverse reactions between the two groups (P>0.05). Conclusions The application of budegforo combined with doxofylline can improve the pulmonary function and clinical efficacy of patients with moderate and severe COPD during exacerbation period, and also play a positive role in reducing MCP-1 and SAA levels.
Pulmonary disease, chronic obstructiveSerum amyloid A proteinMonocyte chemotactic protein 1BudegforoDoxofylline
万方数据
